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Persistent activation of an innate immune response translates
respiratory viral infection into chronic lung disease
Abstract
To understand the pathogenesis of chronic inflammatory disease, we analyzed an experimental mouse
model of chronic lung disease with pathology that resembles asthma and chronic obstructive pulmonary
disease (COPD) in humans. In this model, chronic lung disease develops after an infection with a
common type of respiratory virus is cleared to only trace levels of noninfectious virus. Chronic
inflammatory disease is generally thought to depend on an altered adaptive immune response. However,
here we find that this type of disease arises independently of an adaptive immune response and is driven
instead by interleukin-13 produced by macrophages that have been stimulated by CD1d-dependent T
cell receptor-invariant natural killer T (NKT) cells. This innate immune axis is also activated in the
lungs of humans with chronic airway disease due to asthma or COPD. These findings provide new
insight into the pathogenesis of chronic inflammatory disease with the discovery that the transition from
respiratory viral infection into chronic lung disease requires persistent activation of a previously
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To understand the pathogenesis of chronic inflammatory disease, we analyzed an experimental 
mouse model of a chronic lung disease that resembles asthma and chronic obstructive pulmonary 
disease (COPD) in humans. In this model, chronic lung disease develops after infection with a 
common type of respiratory virus is cleared to trace levels of noninfectious virus. Unexpectedly, 
the chronic inflammatory disease arises independently of an adaptive immune response and is 
driven by IL-13 produced by macrophages stimulated by CD1d-dependent TCR-invariant NKT 
cells. This innate immune axis is also activated in the lungs of humans with chronic airway 
disease due to asthma or COPD. These findings provide new insight into the pathogenesis of 
chronic inflammatory disease with the discovery that the transition from respiratory viral 
infection into chronic lung disease requires persistent activation of a novel NKT cell-macrophage 
innate immune axis.  
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It has been widely speculated that infections are linked to the development of chronic 
inflammatory diseases. Although the connection between infection and chronic disease is 
uncertain, it likely depends on an aberrant immune response. In particular, it is believed that the 
innate immune system mediates the acute response to an infectious agent 1, while an atypical 
adaptive immune response may cause chronic inflammation 2. Furthermore, infection-induced 
alterations in the adaptive immune response that produce T cell or antibody-mediated damage to 
host tissues may underlie the pathogenesis of a variety of common diseases, ranging from asthma 
to diabetes 3-6. For example, it has been suggested that common respiratory viruses, such as 
respiratory syncytial virus (RSV) or human metapneumovirus (hMPV) cause chronic 
inflammation that leads to asthma 7,8. Despite these speculations, we do not know how a chronic 
disease develops long after apparent clearance of the inciting infection.  
To investigate the possible link between acute viral infection and chronic inflammation, we 
developed a mouse model of chronic inflammatory lung disease. The infectious agent used in this 
model is Sendai virus (SeV), which is a mouse parainfluenza virus that is similar to other 
paramyxoviruses (e.g., RSV, hMPV, and human parainfuenza virus) that more commonly infect 
humans. However, mice are relatively resistant to infection with human pathogens such as RSV 
and hMPV. By contrast, SeV replicates at high efficiency in the mouse lung, and SeV infection 
causes injury and inflammation of the small airways (i.e., bronchiolitis) that is indistinguishable 
from the comparable condition in humans. This acute response is followed by a delayed but 
permanent switch to chronic airway disease that is characterized by mucus production (mucous 
cell metaplasia) and increased airway reactivity to inhaled methacholine (airway hyperreactivity) 
9-11. The features of chronic disease manifest in this experimental mouse model are characteristic 
of human chronic airway diseases such as asthma and chronic obstructive pulmonary disease 
(COPD). To obtain insight into the pathogenesis of chronic inflammatory disease, we further 
characterized this distinct mouse model. We identified a new type of innate immune response that 
drives the development of chronic airway disease. This disease mechanism is therefore distinct 
from the dogma that the adaptive immune response is solely responsible for chronic inflammatory 
disease. This unusual immune activity develops after infectious virus is cleared and remaining 
virus in the lung is detectable only by an ultrasensitive PCR-based assay. This new immune axis 
is of special interest because it provides the first indication of how respiratory viral infection is 
linked to the development of chronic inflammatory disease. Moreover, we demonstrate that the 
immune alterations identified using this mouse model are also present in humans with chronic 
inflammatory airway disease due to asthma or COPD.  
 Page 3 
Results 
Persistent disease and IL-13-producing macrophages 
After C57BL/6 mice are infected with SeV, chronic disease is manifest by mucous cell 
metaplasia (with increased lung levels of Muc5ac mRNA and Muc5ac immunostaining) and 
airway hyperreactivity (with increased pulmonary resistance in response to inhaled 
methacholine). Evidence of chronic airway disease is first detected on Day 21 post-inoculation 
(PI), but disease does not become maximal until Day 49 PI (Supplementary Fig. 1). Similar to 
the time course for appearance of airway disease, IL-13 production is also first detected on Day 
21 PI and reaches maximal levels on Day 49 PI. Furthermore, mice treated with an IL-13 decoy 
receptor (sIL-13Rα2-Fc) 12,13 or gene targeted to be IL-13-deficient (Il13–/–), no longer developed 
either mucous cell metaplasia or airway hyperreactivity at any time after viral infection (Fig. 1a, 
Supplementary Fig. 1, and Supplementary Results). By viral plaque-forming assay, infectious 
virus is no longer detectable in the lung by Day 12 PI 9,11,14, and by real-time PCR assay, SeV-
specific RNA is decreased to trace levels by Day 49 PI (Supplementary Fig. 1).  
We next investigated the cellular sources of IL-13 in the lung after clearance of infectious virus. 
At PI Day 21, CD4+ T cells (CD3+CD4+) contributed the highest amount of Il-13 mRNA among 
immune cells in the lung, but macrophages (Mac1+CD68+) became the predominant cellular 
source of Il-13 mRNA by Day 49 PI (Fig. 1b, Supplementary Fig. 2, and Supplementary 
Results). We also found that lung macrophages cultured from SeV (but not SeV-UV) Day 49 PI 
expressed Il-13 mRNA and produced IL-13 protein (Fig. 1c and Supplementary Fig. 2). IL-13 
protein release was further increased by treatment with PMA-ionomycin. With and without PMA-
ionomycin treatment, IL-13 protein production was increased in lung macrophages compared to 
CD4+ T cells and in cells isolated from SeV-inoculated mice compared to SeV-UV-inoculated 
control mice. The observed pattern for IL-13 protein production was consistent with the analysis 
of Il-13 mRNA levels. Furthermore, cells with typical macrophage morphology and CD68 
expression were positive for IL-13 immunostaining in alveolar, interstitial, and epithelial 
locations in wild-type but not in Il13–/– mice (Fig. 1d,e and data not shown). Together, these 
findings provide evidence that lung macrophages are a significant cell source of chronic IL-13 
production after viral infection. Analysis of macrophage-deficient or macrophage-depleted mice 
indicated that IL-13 and Muc5ac production after SeV infection depended on the presence of 
macrophages (Fig. 1f,g and Supplementary Results).  
 Page 4 
NKT cell requirement for macrophage activation 
Analysis of MHC Class II-deficient H2-Ab1–/–, CD4–/–, and CD8a–/– T-cell deficient mice; mice 
that were antibody-depleted of CD4+ T cells, CD8+ T cells, or both CD4+ and CD8+ T cells 
showed the usual development of mucous cell metaplasia and IL-13-producing macrophages after 
viral infection (Supplementary Fig. 3 and Supplementary Results). The unexpected findings 
with T cell blockade led us to investigate whether a new type of cellular mechanism could 
mediate a chronic immune response.  
In addition to T cells and macrophages, we found that an increased number of NKT cells were 
recruited into the lung at Day 49 PI (Fig. 1b, Supplementary Fig. 2, and Supplementary 
Results). Further analysis of the lung NKT cell population indicated that CD4– as well as CD4+ 
NKT cells were a source of Il-13 mRNA in the lung (Fig. 2a–c). Chronic NKT cell activation 
after viral infection was marked by a relatively selective increase in Il-13 mRNA production 
(Supplementary Fig. 4). This pattern of NKT cell activation is distinct from the other 
inflammatory conditions, especially the response to inhaled allergen 15. Nonetheless, the 
persistent production of Il-13 mRNA and the accumulation of NKT cells in the lung suggested 
that this cell population might act in a regulatory role to drive the chronic production of IL-13 by 
macrophages in the lung. The majority of mouse NKT cells express the semi-invariant Vα14-Jα18 
TCR chain that recognizes glycolipid antigen presented by the non-polymorphic CD1d, an MHC 
Class I-like protein 16,17. Consistent with the involvement of NKT cells in this chronic lung 
disease, mice that were deficient in NKT cells due to deletion of the Cd1d gene (Cd1d1–/–) or 
Ja18 gene segment (Traj18–/–) 1,18 had decreases in the levels mucous cell metaplasia and airway 
hyperreactivity as well as IL-13-producing macrophages at PI Day 49 (Fig. 2d–f, 
Supplementary Fig. 4, and Supplementary Results).   
Direct NKT cell-macrophage interaction 
Based on the findings in NKT cell-deficient mice, we postulated that NKT cells might directly 
influence the population of IL-13-producing macrophages in the lung after viral infection. In 
support of a role for NKT cell-dependent recruitment of macrophages, we found that lung 
macrophage levels were decreased in NKT cell-deficient mice and that purified lung NKT cells 
produced increased levels of macrophage chemokines (especially Ccl3) after viral infection (Fig. 
2g,h, Supplementary Fig. 5, and Supplementary Results).  
To determine whether NKT cells might directly stimulate macrophage production of IL-13, we 
established a system for co-culture of purified NKT cells and macrophages. In this system, we 
found that lung NKT cells induced macrophage production of Il-13 mRNA and protein (Fig. 3a 
 Page 5 
and Supplementary Results). The NKT cell effect on macrophage production of IL-13 was not 
found for CD4+ T cells and was inhibited by treatment with anti-CD1d mAb, indicating that this 
NKT cell-macrophage immune axis required direct contact of Jα18-TCR on the NKT cell with 
CD1d on the macrophage. Furthermore, NKT cell-dependent activation of lung macrophages 
was increased by 10-fold in the presence of TCR-CD1d ligand α-GalCer, achieving IL-13 
production levels similar to PMA-ionomycin stimulation of macrophages (Fig. 3b). NKT cell-
derived IL-13 was also necessary for NKT cell-dependent activation of macrophage IL-13 
production, since activation was lost if co-culture was performed with NKT cells from Il13–/– 
mice. To determine whether CD4 expression also influenced NKT cell-macrophage interaction, 
we studied liver NKT cells to provide a more abundant source of CD4+ and CD4– NKT cells. 
Pure preparations of either CD4+ or CD4– liver NKT cells were both capable of activating lung 
macrophages when CD1d glycolipid ligand is provided  (Fig. 3c). Thus, while CD4+ NKT cells 
have been the focus for studies of the response to allergen in the lung 15, it appears that CD4 
expression is not necessary for NKT cell capacity to drive macrophage production of IL-13. 
Instead, NKT cell-dependent macrophage activation appears to depend primarily on invariant 
TCR-CD1d and IL-13–IL-13 receptor (IL-13R) interactions.  
IL-13R signalling and alternatively activated macrophages 
We next examined the downstream events in the NKT cell-macrophage-IL-13 immune axis. 
Analysis of gene expression in the lung indicated that the only significant postviral change among 
148 cytokines or cytokine receptors was induction of Il-13 receptor alpha chain (Il13ra1) gene 
expression (Supplementary Fig. 6). Induction of IL-13Rα1 expression was driven by NKT cells 
and was restricted mainly to lung macrophages (Fig. 4a–c, Supplementary Fig. 7, and 
Supplementary Results). Moreover, IL-13-dependent activation of the IL-13 receptor (IL-13R) 
was necessary for the development of IL-13-producing macrophages (Fig. 4d,e).  
Further examination of microarray data followed by real-time PCR and immunostaining revealed 
that macrophage production of IL-13 was associated with increased macrophage expression of 
Chi3l4, Fizz1, Arg1, Mmp12, and Alox12e genes (Fig. 4f and Supplementary Fig. 7). This 
pattern of gene expression is characteristic of an alternative pathway for activation of 
macrophages 19,20. Like IL-13 production, this type of macrophage activation also depended on 
NKT cells and IL-13–IL-R interaction, since it was decreased in Cd1d1–/– and Il13–/– mice after 
viral infection (Fig. 4f–h, Supplementary Fig. 7, and Supplementary Results). Together, the 
findings imply that increased levels of macrophage IL-13R could respond to IL-13 produced by 
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NKT cells or macrophages to amplify macrophage production of IL-13 and consequent 
macrophage activation via the alternative pathway.  
NKT cell-macrophage pathway in human chronic airway disease 
We next determined if there was evidence of an activated NKT cell-macrophage immune axis in 
humans with chronic airway disease. Based on the established association of acute respiratory 
viral infection and the subsequent development of chronic asthma, we first investigated whether 
the NKT cell-macrophage-IL-13 pathway was activated in subjects with asthma. We detected an 
increased number of macrophages that immunostained positive for IL-13 in bronchoalveolar 
lavage (BAL) samples obtained from subjects with severe asthma relative to samples from 
healthy control subjects (Supplementary Fig. 7).  
To obtain suitable samples of lung tissue for more detailed analysis, we analyzed lung tissue 
obtained from lung transplant recipients with severe COPD and lung donors that did not have 
COPD. The lung tissue obtained from COPD subjects exhibited significant mucous cell 
metaplasia as evidenced by an increased number of MUC5AC+ mucous cells and higher levels of 
MUC5AC mRNA in the lung (Fig. 5a,b). Consistent with our findings in the mouse model of 
chronic lung disease, we also detected an increased level of IL-13 mRNA in COPD lungs with 
chronic mucous cell metaplasia (Fig. 5b). The increase in IL-13 mRNA levels was associated 
with an increase in the number of cells that immunostained for IL-13 protein in COPD lung tissue 
(Fig. 5c). These IL-13+ cells were identified as lung macrophages based on typical morphology 
and positive immunostaining for CD68. Furthermore, these IL-13+CD68+ macrophages were 
found at increased numbers in lungs from COPD subjects compared to non-COPD controls (Fig. 
5d). In addition, we were able to detect NKT cells in lung tissue based on immunostaining for the 
invariant Vα24 T cell receptor chain (Fig. 5e). In concert with increased levels of mucous cells, 
IL-13 production, and IL-13+ macrophages, we also found that Vα24+ NKT cells were present in 
increased numbers in the lungs of subjects with COPD compared to non-COPD controls (Fig. 5f). 
Together, the findings suggest that an innate NKT cell-macrophage-IL-13 immune axis may be 
activated in human disease conditions that are similar to the virus-induced mouse model of 
chronic airway disease. 
DISCUSSION 
This report defines a new immune pathway for the development of chronic inflammatory lung 
disease (diagrammed in Fig. 6). To identify this pathway, we analyzed an experimental model of 
chronic airway disease that develops after viral infection. In this model, the inciting virus remains 
detectable in the lung at trace levels, and an invariant CD4– NKT cell population is activated in 
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the lung. This cell population appears to be specially programmed to recruit and activate lung 
macrophages. Activation of macrophages requires NKT cell production of IL-13 and direct 
contact between the invariant Vα14Jα18-TCR on lung NKT cells and CD1d on macrophages. 
The activated lung macrophages produce IL-13 and overexpress the IL-13 receptor, and this 
combination of events establishes a positive feedback loop that promotes the persistent expression 
of IL-13 as well as other IL-13-induced genes that are characteristic of an alternative pathway for 
macrophage activation. The persistent production of IL-13 causes chronic mucous cell metaplasia 
and airway hyperreactivity that are characteristic of chronic inflammatory airway diseases such as 
asthma and COPD. This analysis provides the first evidence that IL-13-producing macrophages 
are present in increased numbers in the lungs of patients with asthma and COPD. We also show 
that an orthologous population of invariant Vα24Jα18-TCR NKT cells is found at increased 
levels in the lung tissue of patients with COPD. Together, these findings in this experimental 
model identify an innate NKT cell-macrophage immune axis that enables a viral infection to 
initiate a chronic inflammatory lung disease. Analysis of human lung samples obtained from 
patients with asthma and COPD indicate that components of this pathway may also contribute to 
chronic airway diseases that are common in the human population.  
Our findings for NKT cell-macrophage function are distinct from previous reports of immune 
abnormalities in chronic inflammatory disease in general, and lung disease in particular. For 
example, invariant NKT cells were necessary for airway hyperreactivity in a mouse model of 
allergen-induced asthma and were found in increased numbers in allergic asthma patients 15,21-23. 
However, subsequent reports indicated that NKT cells were not necessary for airway 
inflammation in the mouse model and that the numbers of invariant NKT cells in BAL fluid or 
endobronchial biopsies were no different from normal in either asthma or COPD patients 24,25. 
The present findings highlight the need for a more complete assessment of the innate immune 
response. Thus, respiratory viral infection provided a more effective stimulus than acute allergen 
challenge for chronic activation of the immune system in an experimental mouse model. In 
addition, a proper assessment of a small subset of lymphocytes was better accomplished with the 
relatively larger amounts of sample tissue that can be obtained from lung resection or 
transplantation in patients with airway disease. Finally, a synchronized analysis of the mouse 
model in combination with human patients was essential to establish a previously unrecognized 
role for NKT cells and IL-13-producing macrophages in the inflammatory process that drives 
chronic disease.  
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The presence of a persistent innate immune response suggests that there must be ongoing immune 
stimulation. In that regard, we did not detect any evidence of infectious virus by 2 weeks after 
inoculation. However, using highly sensitive PCR probes and virus-clean isolation rooms, we 
were able to detect low levels of virus-specific RNA in lung tissue until at least PI Day 49. 
Whether viral persistence is necessary for a chronic immune response is still being defined. For 
example, conventional DCs (cDCs) are sites of virus uptake, are activated acutely and perhaps 
chronically after SeV infection, and are capable of activating NKT cells at low levels of antigen 
26-28. Our results (like that of others) indicate that invariant NKT cells may also react to CD1d-
expressing macrophages by a mechanism that does not require but can be enhanced by high-
affinity agonists such as αGalCer 29. Additional work must therefore be directed at the cause of 
chronic NKT cell-macrophage activation after viral infection, and the possibility that viral 
remnants contained in cDCs, macrophages, or other cell types might drive this process.  
Our results provide a model for persistent activation of an innate immune axis and present a new 
paradigm for the pathogenesis of chronic inflammatory lung disease. Previously, immune 
pathways promoting IL-13 production were viewed primarily as protection against parasitic 
infection 19,30. Infection by extracellular parasites is known to stimulate a T helper type 2 (Th2)  
cell response with production of IL-4 and IL-13 that can in turn activate macrophages by an 
alternative pathway 19. A similar type of response is found after allergen challenge in mice and in 
allergic asthma in humans 31,32. By contrast, intracellular bacteria and viruses characteristically 
activate a Th1 response with production of IFN-γ and consequent activation of macrophages via 
the classical pathway. Development of this IFN-dependent pathway is proposed to downregulate 
the allergic response and protect against allergic airway disease 33. However, these general 
patterns were defined largely defined within the context of an acute immune response 34. The 
present observations indicate that viruses can also trigger long-term activation of NKT cells and 
achieve chronic production of IL-13 by macrophages themselves. In combination with IL-13 
receptor signaling, this innate mechanism can establish a state of persistent macrophage 
activation that is typical of the alternative pathway. Presumably this mechanism evolved to mount 
a long-term innate immune response independently of CD4+ or CD8+ T cells and thereby enable a 
response to low-level endemic pathogens that are poorly presented by MHC but adequately 
presented by CD1d. However, in at least some genetic backgrounds, we show that this type of 
innate immune activation can also lead to the development of chronic inflammatory airway 
disease in an experimental model and that similar immune activation occurs in patients with 
asthma and COPD. Indeed, there is already a well-established clinical relationship between acute 
viral infection and the subsequent development of chronic asthma later in childhood and perhaps 
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adulthood 7. Other clinical studies will need to be done to test whether patients with COPD may 
share this same link to earlier infection. The present results provide new markers of innate 
immune activation to follow how infection leads to chronic inflammatory disease in this group of 
patients and perhaps others.  
METHODS 
For details, see Supplementary Methods online. 
Mice generation and treatment. We received breeding pairs of Il13–/– mice from Tom Wynn (NIAID, 
Bethesda, MD), Cd1d1–/– mice from Albert Bendelac (Univ. Chicago, Chicago, IL), and Traj18–/– mice 
from Masaru Taguchi (RIKEN, Yokohama, Japan). We obtained Il4–/–, Op/op, and wild-type C57BL/6J 
mice from Jackson Laboratory and H2-Ab1–/– mice from Taconic Farms. All mice strains were fully 
backcrossed onto the C57BL/6 background. For IL-13 blockade, we obtained sIL-13Rα2-Fc from Sandy 
Goldman (Wyeth Pharmaceuticals) and administered this agent at 200 µg/mouse by subcutaneous injection 
beginning on PI Day 12 and then at 3-day intervals. For macrophage depletion, we treated mice with 
clodronate-containing or control liposomes prepared as described previously 35. We administered liposomes 
by intraperitoneal or retro-orbital intravenous injection using 2 mg at Day 14 after inoculation and then 0.5 
mg at 3-d intervals thereafter until d 21 or 49 after inoculation, and macrophage depletion was monitored as 
described previously 35. We used Sendai virus (Sendai/52, Fushimi Strain) to inoculate mice intranasally 
with virus or UV-inactivated virus as described previously 9,10,35,36. We delivered SeV at 1 x 105 pfu per 
mouse but reduced the inoculum to 0.5 x 105 pfu for immunocompromised mice (Op/op and H2-Ab1–/– 
mice) to ensure survival. The Animal Studies Committee of Washington University School of Medicine 
approved all experimental protocols. 
Analysis of mRNA and SeV-specific RNA. We purified RNA from homogenized lung tissue or isolated 
cells using the RNeasy mini kit (Qiagen), and we made cDNA from RNA with the High Capacity cDNA 
Archive kit (Applied Biosystems). We quantified target mRNA and viral RNA levels with real-time PCR 
using specific fluorogenic probe-primer combinations and Fast Universal PCR Master Mix systems 
(Applied Biosystems). We performed oligonucleotide microarray analysis as described previously 11,35.  
Cell isolation and culture. We purified immune cell subsets from lung cell suspensions by FACS using rat 
anti-mouse mAb and a Mo-Flo high-speed flow cytometer (Dako Cytomation). For macrophage-NKT cell 
co-culture, we purified macrophages from lung cell suspensions using OptiPrep (Sigma-Aldrich) followed 
by adherence to 8-well Lab-Tek II chambers (Nunc). In some experiments, we blocked macrophages with 
anti-mouse CD16/CD32 (1 µg per 1 x 106 cells) for 15 min and then incubated them with anti-CD1d mAb 
or rat IgG2b control (50 µg/ml) for 30 min at 4 °C. We purified lung and liver NKT cells by FACS after 
initial enrichment with the MACS Separator (Miltenyi-Biotec) using FITC-labeled anti-CD3e mAb plus 
APC-labeled α-GalCer-analogue (PBS57)-loaded CD1d tetramer (supplied by the NIH Tetramer Facility) 
and anti-APC microbeads (Miltenyi-Biotec). We cultured macrophages and NKT cells (both >99% purity) 
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at 5 x 104 and 5 x 103 cells per well, respectively, for 24 h at 37 °C in RPMI with 10% FBS. We collected 
cell media for ELISA, and then washed off NKT cells and lysed adherent macrophages in TRIzol for RNA 
isolation and real-time PCR assay.  
Immunohistochemistry. We performed immunostaining with brightfield microscopy as described 
previously 9,10,36. For immunofluorescence, we used paraffinized sections that were hydrated and incubated 
in Antigen Unmasking Solution (Vector Labs) for antigen retrieval. We visualized staining with tyramide 
signal amplification with Alexa Fluor 555 or 594 (Invitrogen). We performed photomicrography and 
quantification of reporter by cell counting (cells per mm of basement membrane or mm3 of lung tissue) 
using Image J and NIH Image software as described previously 10,36,37.  
Human subject samples. We obtained samples from COPD patients undergoing lung transplantation and 
non-COPD lung donors as described previously 10. We performed immunofluorescence microscopy using 
biotinylated goat anti-human IL-13 Ab (R&D Systems, 4 µg/ml), biotinylated mouse anti-human CD68 
mAb (clone KP1, DakoCytomation, 5 µg/ml), and mouse anti-Vα24 mAb (Beckman Coulter, 2 µg/ml) as 
described above for mouse lung tissue sections. Sections were blocked with 5% goat serum or mouse IgG1 
(eBioscience), stained with primary Ab and then with HRP-conjugated anti-mouse IgG secondary Ab, or 
avidin-HRP (Vector ABC Elite System). The Washington University Human Studies Committee approved 
all human studies, and informed consent was obtained from all human subjects. 
Statistical analysis. We analyzed values for target mRNA, mucous cell, and airway reactivity levels using 
a one-way analysis of variance (ANOVA) for a factorial experimental design. If significance was achieved 
by one-way analysis, we performed post-ANOVA comparison of means using Scheffe's F test. We 
compared PCR data by unpaired Student’s t-test. If variances were unequal, we applied Welch’s correction. 
Significance level for all analyses was 0.05. All values represent mean ± SEM. 
Microarray data was deposited in the National Center for Biotechnology Information (NCBI) Gene 
Expression Omnibus (GEO) under series accession number GSE10964. 
Note: Supplementary information is available on the Nature Medicine website.  
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Figure Legends 
Figure 1. IL-13-producing macrophages drive chronic airway disease after viral infection. (a) Wild-type 
(WT) and Il13–/– mice were inoculated with SeV or UV-inactivated SeV (SeV-UV), and WT mice were 
untreated (NT) or treated with control IgG or sIL-13Rα2-Fc from Day 12 to 49 PI. Lung levels of Muc5ac 
mRNA were determined at Day 21 and 49 PI. (*) indicates a significant decrease from corresponding 
untreated control. (b) Lung cell subsets were isolated at Day 21 and 49 PI and were analyzed for Il-13 
mRNA levels. Values represent Il-13 mRNA per cell fraction. (c) Lung CD4+ T cells and macrophages 
from Day 49 PI were cultured without or with PMA (20 ng/ml) and ionomycin (500 ng/ml) for 24 h at 37 
°C, and IL-13 was determined in cell culture media. (*) indicates a significant difference from 
corresponding SeV-UV control. (d) Airway sections from WT or Il13–/– mice at Day 49 PI were 
immunostained for IL-13. (e) Airway sections from WT mice at Day 49 PI were immunostained for IL-13 
and CD68. Bars = 20 µm. (f) Op/op mice at Day 49 PI were assessed for lung Il-13 and Muc5ac mRNA 
levels. (*) indicates a significant decrease from corresponding SeV-UV control value. (g) WT mice were 
assessed after being treated with clodronate (+) or empty control (–) liposomes from Day 12 to 49 PI. (*) 
indicates a significant decrease from corresponding value for empty liposome treatment.  
Figure 2. Activated NKT cells are required for chronic IL-13-producing macrophages in the lung after 
viral infection. (a) CD4+ and CD4– NKT cells were purified from mouse lungs at Day 0, 21, and 49 PI and 
were analyzed for Il-13 mRNA levels. Values represent units of Il-13 mRNA per cell fraction. (b) 
Corresponding number of cells in each NKT cell fraction. (c) Corresponding values for units of Il-13 
mRNA per cell. For (a-c), (*) indicates a significant difference from Day 0 PI. (d) WT and Cd1d1–/– mice 
were inoculated with SeV or SeV-UV, and lung sections were immunostained for IL-13+CD68+ cells. (e) 
Using conditions in (d), mouse lungs were analyzed for Il-13 and Muc5ac mRNA levels. (f) WT and 
Traj18–/– mice were inoculated with SeV or SeV-UV, and lungs at Day 49 PI were analyzed for Il-13 and 
Muc5ac mRNA levels. (g). WT and Cd1d1–/– mice were inoculated with SeV or SeV-UV, and lung sections 
at Day 49 PI were immunostained for CD68+ cells. For (d-g), (*) indicates a significant decrease from 
corresponding value for WT mice. (h) CD4+ and CD4– NKT cells were purified from mouse lungs at PI 
Day 49 and were analyzed for Ccl3 mRNA by real-time PCR. (*) indicates a significant increase from 
SeV-UV.  
Figure 3. Direct lung NKT cell-macrophage interaction generates IL-13-producing macrophages. (a) Lung 
macrophages were cultured alone or with lung NKT cells or CD4+ T cells for 24 h at 37 °C. Lung 
macrophages were also treated with anti-CD1d mAb or control IgG2b. (b) Culture conditions are the same 
as (a), but also include stimulation using PMA-ionomycin or α-GalCer (αGC). (c) Conditions are the same 
as (b), but macrophages were cultured with CD4+ and CD4– liver NKT cells. For (a-c), adherent 
macrophages were analyzed for Il-13 mRNA, and cell media was analyzed for corresponding IL-13 protein 
levels. Note 10-20-fold increase in y-axis for (b,c) compared to (a). (*) indicates a significant increase from 
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macrophage and NKT cell alone, and (**) indicates a significant decrease from corresponding value for 
lung NTK cell-macrophage co-culture.  
Figure 4. NKT cells drive IL-13R expression to upregulate IL-13 production and alternative activation of 
macrophages after viral infection. (a) Lung levels of Il-13ra1 mRNA in WT, Cd1d1–/–, and Il13–/– mice at 
Day 49 PI. (b) Levels of Il-13ra1 mRNA in macrophages (Mac1+ and CD3–NK1.1–GR1–B220–CD11c–) 
and non-macrophages (Mac1–) purified from WT and Cd1d1–/– mice at Day 49 PI. Similar results were 
obtained for Mac1+CD68+ versus Mac1+CD68– cell subsets (data not shown). For (a,b), (*) indicates a 
significant increase from SeV-UV. (c) Representative photomicrographs of lungs sections immunostained 
for CD68 and Il-13rα1 at Day 49 PI. Bar = 50 µm. (d) Quantitative analysis of IL-13+CD68+ macrophages 
in mice inoculated with SeV-UV or SeV and treated with either control IgG or sIL-13Rα2-Fc from Day 12 
to 49 PI. (e) Lung levels of Il-13 mRNA determined for conditions in (d). For (d,e), (*) indicates significant 
decrease from control IgG. (f) Representative photomicrographs of lungs sections immunostained for CD68 
and Chi3l3/4 at Day 49 PI. Bar = 50 µm. (g) Lung levels of Chi3l3/4 mRNA in WT, Il13–/–, and Cd1d1–/– 
mice at Days 21 and 49 PI. (h) Levels of Chi3l3/4, Arg1, and Mmp12 mRNA in lung macrophages purified 
from WT and Cd1d1–/– mice at Day 49 PI. For (g,h), (*) indicates a significant increase from corresponding 
SeV-UV value, and (**) indicates a significant decrease from corresponding WT control value.  
Figure 5. Increased IL-13-producing macrophages and Vα24-expressing NKT cells in humans with COPD 
and mucous cell metaplasia. (a) Representative photomicrographs of lung sections from a COPD subject 
undergoing lung transplantation and a non-COPD lung transplant donor were immunostained for 
MUC5AC. (b) Levels of MUC5AC and IL-13 mRNA in lungs from COPD subjects and non-COPD 
controls. (c) Representative photomicrographs of lung sections from COPD and non-COPD subjects that 
were immunostained for IL-13 and CD68. Arrows indicate an IL-13+CD68+ macrophage; arrowheads 
indicate an IL-13–CD68+ macrophage. (d) Quantitative analysis of data from (c) in lungs from COPD 
subjects and non-COPD controls. (e) Representative photomicrographs of lung sections from COPD 
subjects that were immunostained for Vα24. Arrows indicate Vα24+ NKT cells. (f) Quantitative analysis of 
data from (e) in COPD subjects and non-COPD lung transplant donors. All bars = 50 µm. For (b,d,f), n = 5 
per group, and (*) indicates a significant increase from non-COPD control value. 
Figure 6. Scheme for an NKT cell-macrophage immune axis leading to chronic airway disease after viral 
infection. Virus may directly or indirectly facilitate CD1d-dependent antigen presentation and consequent 
activation of invariant CD4– NKT cells. NKT cells then interact directly with lung macrophages via contact 
between invariant Vα14 TCR and glycolipid-loaded CD1d. This interaction leads to increased expression 
of IL-13R and production of IL-13 that drives a positive feedback loop to amplify IL-13 production and 
alternative activation of macrophages, including Chi3l3/4, Fizz1, Mmp12, Arg1, and Alox12e gene 
expression. Persistent IL-13 production also drives differentiation of airway epithelial cell precursors 
towards mucous cells (mucous cell metaplasia) and airway smooth muscle cells to become more reactive to 
contractile agonists (airway hyperreactivity or AHR).  
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IL-13 dependence of persistent disease traits 
Neither pulmonary emphysema nor fibrosis is observed at any time after viral infection (data not 
shown). The inhibition of airway hyperreactivity was independent of any changes in baseline 
airway caliber (Supplementary Fig. 1). We found no difference in peak viral load at Day 3-5 PI 
or the 6 log-fold decrease to trace levels of virus-specific RNA by Day 49 PI in wild-type versus 
Il13–/– mice. Therefore, the inhibition of chronic lung disease in Il13–/– mice does not appear to 
depend on any difference in viral replication or clearance. (Supplementary Fig. 1).  
IL-13 production by macrophages 
For CD4+ T cells and macrophages, the contribution to lung Il-13 mRNA levels was based on an 
increased number of cells recruited to the lung as well as increased production of Il-13 mRNA 
per cell (Supplementary Fig. 2). Other minor sources of Il-13 mRNA included NK cells and 
NKT cells. However, there was no detectable Il-13 mRNA produced by mast cells, basophils, 
neutrophils, dendritic cells (DCs), B cells, or CD8+ T cells. In some sections, we found a marked 
accumulation of macrophages in the airway epithelium that was not observed in uninfected 
control mice (data not shown). The high production of IL-13 per macrophage compared to other 
cell types (e.g., CD4+ T cells) may be responsible for the detection of CD68+IL-13+ but not 
CD4+IL-13+ cells in tissue. 
To determine whether macrophages are necessary for chronic lung disease, we first studied 
op/op mice that are macrophage-deficient due to a loss of function mutation in the Csf3 (also 
known as G-CSF) gene. Since macrophages are required for antiviral defense 15, these mice were 
infected with a reduced viral inoculum. Compared to wild-type mice inoculated with the same 
amount of SeV, the op/op mice exhibit markedly decreased levels of Il-13 and Muc5ac gene 
expression. To preserve the ability to develop an acute immune response to viral infection, we 
next studied wild-type mice that were treated with clodronate-containing liposomes using a 
protocol that selectively depletes lung macrophages 15. Liposome treatment was started after 
clearance of infectious virus to avoid any possible effect on the acute infection. Thus, there was 
no need to decrease the viral inoculum to preserve survival, and the usual inoculum was 
administered in these experiments. We found no difference between control and clodronate-
liposome treated mice in the levels of Il-13 or Muc5ac mRNA at Day 21 PI, which was 
consistent with a lack of IL-13 production by macrophages at this early time point. However, 
macrophage-depleted mice exhibited significantly decreased levels of Il-13 and Muc5ac gene 
expression at Day 49 PI compared to mice that were treated with empty liposomes. 
Immunostaining of lung sections indicated that clodronate-treated mice were depleted of IL-13-
producing macrophages (data not shown). The loss of IL-13-producing macrophages caused a 
decrease in Il-13 mRNA and mucous cell metaplasia that was in proportion to the macrophage 
contribution to total Il-13 mRNA production in the lung at Day 49 PI.  
NKT cell requirement for macrophage activation 
We investigated whether persistent pressure from another part of the immune system might be 
necessary to activate macrophages for prolonged periods after viral infection. As noted in the 
Introduction, this type of chronic pressure is generally attributed to activation of the adaptive 
immune response. However, we found that MHC Class II-deficient H2-Ab1–/– mice that lack 
most CD4+ T cells continued to develop mucous cell metaplasia in concert with increased Il-13 
and Muc5ac mRNA levels after viral infection (Supplementary Fig. 3). Similar to wild-type 
mice, these immunocompromised mice contained only trace levels of viral RNA in the lung by 
Day 49 PI (Supplementary Fig. 3). Furthermore, we found the same susceptibility to develop 
chronic airway disease after viral infection in CD4–/– and CD8a–/– T-cell deficient mice (data not 
shown). To fully avoid interfering with the acute antiviral response, we also achieved T cell 
depletion using antibody treatment that (like sIL-13Rα2-Fc and clodronate treatment) was not 
initiated until after clearance of infectious virus. Similar to mice with a genetic T cell deficiency, 
we found that mice that were antibody-depleted of CD4+ T cells, CD8+ T cells, or both CD4+ 
and CD8+ T cells also showed the expected increase in the number of IL-13-producing 
macrophages, induction of Il-13 or Muc5ac gene expression, and mucous cell metaplasia after 
viral infection (Supplementary Fig. 3 and data not shown). These findings do not exclude a role 
for T cells in the development of chronic lung disease after viral infection. Indeed, we find that 
CD4+ T cells are a significant source of IL-13 production at PI Day 21 and 49. The findings with 
T cell blockade do, however, suggest that other types of immune cells may also influence the 
chronic disease that develops after viral infection. 
The increased population of NKT cells in the lung was detected using either α-
galactosylceramide (α-GalCer) analogue-loaded CD1d-tetramer or by staining for NK1.1+CD3+ 
cells (data not shown). CD4– NKT cells appeared in greater numbers in the lung at Day 49 PI 
and produced the same or higher levels of Il-13 mRNA per cell at Day 21 and 49 PI compared to 
CD4+ NKT cells. In contrast to CD4+ NKT cells, CD4– NKT cell production of Il-13 mRNA was 
not accompanied by any increase in Il-4 mRNA at Day 21 or 49 PI (Supplementary Fig. 4). 
Even for CD4+ NKT cells, the level of Il-4 mRNA production was relatively low at Day 49 PI. 
This pattern of low Il-4 mRNA production was also found for CD4+ T cells at Day 49 PI, and, 
consistent with these findings, treatment with an anti-IL-4 mAb caused no change in the 
development of chronic lung disease after viral infection (Supplementary Fig. 4 and data not 
shown). Similarly, NKT cell activation was not accompanied by any increase in Ifn-β or Ifn-γ 
mRNA production by Day 49 PI (Supplementary Fig. 4). The involvement of CD4– NKT cells 
in driving chronic inflammation is consistent with our finding that Il-13 or Muc5ac mRNA 
production persisted despite treatment with CD4-depleting mAb (Supplementary Fig. 3). 
In studies of NKT cell-deficient mice, the decreases in IL-13-producing macrophages as well as 
Il-13 and Muc5ac mRNA levels in the lung was observed at Day 49 PI but was not observed at 
Day 21 PI. This finding was consistent with the time course for increased macrophage 
production of IL-13 and with the effects of macrophage depletion. Furthermore, Cd1d1–/– mice 
at Day 49 PI also had decreased airway hyperreactivity relative to wild-type control mice, and 
this decrease was independent of any changes in baseline airway caliber (Supplementary Fig. 
4). We also observed similar inhibition of virus-induced Il-13 and Muc5ac gene expression in 
the lungs of Traj18–/– mice. In both strains, lung levels of viral RNA were similar to wild-type 
mice (Supplementary Fig. 4). Together, these findings indicated that NKT cells (independent of 
CD1d-dependent actions on NKT cells or APCs) were necessary for chronic lung disease after 
viral infection. 
Direct NKT cell-macrophage interaction 
We reasoned that NKT cells could act by recruiting macrophages to the lung and by activating 
macrophage production of IL-13. A role for NKT cell-dependent recruitment of macrophages 
was substantiated when we found that the usual increase in lung macrophages at Day 49 PI that 
was found in wild-type mice was absent in Cd1d1–/– mice. In support of a mechanism for NKT 
cell-dependent recruitment of macrophages, we found that purified lung NKT cells released 
biologically relevant amounts of macrophage chemokines (predominantly Ccl3) after stimulation 
with PMA-ionomycin (Supplementary Fig. 5). Furthermore, lung NKT cells isolated from Day 
49 PI produced increased levels of macrophage chemokine mRNA compared to NKT cells from 
mice without SeV-induced lung disease (Supplementary Fig. 5). The predominant chemokine 
mRNA produced by NKT cells after viral infection was Ccl3 (consistent with the profile for 
chemokine production at the protein level), and increased Ccl3 (as well as Ccl2 and Ccl4) 
mRNA levels were found exclusively in CD4– rather than CD4+ NKT cells (consistent with the 
increased activity of CD4– NKT cells in chronic lung disease after viral infection). 
In our co-culture system, we used NKT cells and macrophages from mice without SeV 
inoculation to achieve low background levels of IL-13 production. We used α-GalCer-analogue-
loaded CD1d-tetramer to isolate NKT cells and thereby obtained the same invariant NKT cell 
population that was targeted in Cd1d1–/– and Traj18–/– mice. The system was also constructed so 
that NKT cells could be removed after cell-cell interaction to allow for monitoring IL-13 
production derived only from adherent macrophages. We found that liver NKT cells were 
somewhat less effective than lung NKT cells in driving macrophage activation, in that liver 
NKT cells required α-GalCer ligand to stimulate macrophage production of Il-13 mRNA. 
IL-13R signalling and alternatively activated macrophages 
To determine whether persistent activation of this immune axis was driven by upregulation of 
cytokines (including IL-13) or cytokine receptors in vivo, we used oligonucleotide microarrays 
to analyze mRNA isolated from the lungs of mice at Days 21 and 49 PI (Supplementary Fig. 
6). Real-time PCR analysis of whole lung samples indicated that Il-13ra1 mRNA was 
upregulated in wild-type and Il13–/– mice but not in Cd1d1–/– mice, indicating that NKT cells 
stimulated an increase in Il-13ra1 mRNA. The relatively small increase in Il-13ra1 mRNA after 
viral infection in whole lung samples suggested that increased expression might be restricted to a 
subpopulation of lung cells such as macrophages. We therefore analyzed Il-13ra1 mRNA in 
macrophages that were FACS-purified from whole lung samples. Relative to whole lung 
samples, we found that there was a much greater increase of Il-13ra1 mRNA in lung 
macrophages isolated after viral infection, and this increase was also blocked in Cd1d1–/– mice. 
Similarly, IL-13rα1 was co-localized with the macrophage marker CD68 as well as with IL-13 
in lung tissue sections obtained from mice on PI Day 49 by immunostaining (Supplementary 
Fig. 7). Furthermore, blockade of IL-13 action by sIL-13Rα2-Fc caused a marked decrease in 
the levels of IL-13-producing macrophages, which, in turn, caused a decrease in Il-13 mRNA 
levels in the lung.  
The microarray gene expression data was re-examined to identify any additional chronic 
changes in gene expression after viral infection. The mRNAs encoding chitinase-like proteins 
(Chi3l3/4 and Fizz1),  arginase (Arg1), matrix metalloproteinase (Mmp12), and arachidonate 12-
lipoxygenase (Alox12e) were significantly up-regulated on Day 49 PI, and these same mRNAs 
were also upregulated but to a lesser degree on Day 21 PI (Supplementary Fig. 6). Real-time 
PCR assays for these gene products confirmed the microarray data (Supplementary Fig. 7). 
Furthermore, these changes were completely blocked in Il13–/– mice, and they were partially 
inhibited in Cd1d1–/– mice after viral infection (Supplementary Fig. 7, and data not shown). 
Immunostaining for Chi3l3/4 protein indicated that the increase in the amount of this protein 
was localized predominantly to lung macrophages and occurred at the same time as the increases 
in Chi3l3/4 mRNA levels (Supplementary Fig. 7 and data not shown). Moreover, FACS-
purified lung macrophages exhibited upregulation of the same markers of alternative activation 
as whole lung samples at Day 49 PI as well as downregulation of expression in NKT cell-
deficient mice (Supplementary Fig. 7). 
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Supplementary Figure 1. Viral induction of IL-13 production causes mucous cell 
metaplasia. (a) WT mice were inoculated with SeV, and lung Muc5ac and Il-13 mRNA 
levels were determined at the indicated days PI. (b) WT mice were inoculated with 
SeV or SeV-UV, treated with control IgG or sIL-13Rα2-Fc from Day 12 to 49 PI, and 
lung sections were immunostained for Muc5ac. Bar = 20 µm. Il-13–/– mice and isotype 
control IgG showed no signal above background (data not shown). (c) Quantification 
of Muc5ac+ cells from (b). (d) WT and Il13–/– mice were inoculated as in (b) and 
assessed for pulmonary resistance (RL) versus concentration of inhaled methacholine. 
(e) For conditions in (d), corresponding values for baseline RL. (f) WT and Il13–/– mice 
were inoculated with SeV, and lungs were analyzed for SeV-specific RNA. For (a, 
d,e,f), (*) indicates a significant increase from Day 0, SeV-UV; for (c), (*) indicates a 
significant decrease from no treatment control. 
Supplementary Figure 2 
 
Supplementary Figure 2. IL-13 production in lung macrophages and 
other immune cell types. (a) WT mice were inoculated with SeV, and 
lung cell subsets were isolated from mice at Day 21 and 49 PI. Each 
cell fraction was analyzed for Il-13 mRNA levels. Values represent Il-
13 mRNA per cell for each cell fraction. (b) Corresponding number of 
cells in each Il-13-expressing cell fraction. For (a,b), (*) indicates a 
significant increase from Day 0 PI. (e) Purified lung macrophages from 
Day 49 PI were analyzed for Il-13 mRNA at the indicated times after 
isolation. (*) indicates a significant difference from corresponding 
SeV-UV control. 
Supplementary Figure 3 
Supplementary Figure 3. Effect of T cell depletion on mucous cell 
metaplasia after viral infection. (a) H2-Ab1–/– mice were inoculated 
with SeV at 0.5 x 105 pfu, and lung sections were immunostained 
for Muc5ac at Day 0, 21, and 49 PI. Bar = 20 µm. (b) From 
conditions in (a), quantification of Muc5ac+ cells. (c) For conditions 
in (a), lungs were analyzed for Il-13 and Muc5ac mRNA and SeV 
RNA levels. For (b,c), (*) indicates a significant increase from Day 
0 PI. (d) WT mice were inoculated SeV or SeV-UV and treated 
with control IgG, anti-CD4 mAb, and/or anti-CD8a mAb from Day 
12 to 49 PI. Lung sections from Day 49 PI were immunostained for 
Il-13+CD68+ cells, and corresponding lungs were analyzed for Il-13 
and Muc5ac mRNA levels. (*) indicates a significant increase from 
SeV-UV.  
 
Supplementary Figure 4 
Supplementary Figure 4. Characterization of lung NKT cell function after viral infection. (a) 
Representative cytograms and gating strategy for analysis of lung NKT cells by flow cytometry 
using forward and side scatter as well as FITC-labeled anti-CD3e mAb and APC-labeled CD1d 
tetramer. (b) Using the strategy in (a) plus anti-CD4 mAb, CD4+ and CD4– NKT cells were 
purified from WT mice at Day 0, 21, and 49 PI, and each subset was analyzed for Ifn-β, Ifn-γ, 
and Il-4 mRNA level. (c) WT mice were inoculated with SeV or SeV-UV, treated with anti-IL-
4 mAb or isotype control Ig from Day 14 to 21 or 49 PI, and lung RNA was analyzed for Il-13 
and Muc5ac mRNA levels. (d) WT and Cd1d1–/–mice were assessed for airway reactivity at 
Day 49 PI (n = 5-10 mice per group). (e) For conditions in (d), corresponding values for 
baseline RL. (f) Cd1d1–/– and Traj18–/– mice were inoculated with SeV, and lungs were 
analyzed for SeV RNA levels. For (b,e,f), (*) indicates a significant increase from Day 0 PI.  
 
Supplementary Figure 5 
 
Supplementary Figure 5. NKT cell production of 
chemokines for lung macrophages. (a) FACS-purified CD4+ 
and CD4– NKT cells (2 x 105 cells/ml) from mouse lungs at 
PI Day 49 were cultured in RPMI with 10% FBS and PMA-
ionomycin for 1 d at 37 °C, and cell culture media were 
analyzed for chemokine levels by multiplex bead-based 
assay. (b) CD4+ and CD4– NKT cells from mouse lungs at PI 
Day 49 were analyzed for Ccl2, Ccl4, and Ccl5 mRNA by 
real-time PCR. (*) indicates a significant increase from SeV-
UV.  
 
Supplementary Figure 6 
 
Supplementary Figure 6. Oligonucleotide microarray analysis of lung mRNA after viral 
infection. Scatter plot depicts normalized gene expression in SeV-UV- versus SeV-inoculated 
mice at PI Days 21 and 49. Red lines indicate differential expression ≥ 2 SD from the mean 
(dashed line).  
Supplementary Figure 7 
 
Supplementary Figure 7. IL-13R expression and alternative activation of macrophages. 
(a) Representative photomicrographs from lung sections at PI Day 49 immunostained for 
CD68, IL-13, and IL-13Rα1 and imaged by laser confocal scanning microscopy. Bar = 
50 µm. (b) Lung levels of Chi3l3/4 and Fizz1 mRNA at indicated SeV PI Days. (c) 
Representative photomicrographs from lung sections at PI Day 49 immunostained for 
Chi3l3/4. Bar = 50 µm. (d) Lung levels of Arg1 and Mmp12 mRNA in WT, Il-13–/–, and 
Cd1d–/– mice at PI Day 49. (e) Levels of Chi3l3/4, Arg1, Mmp12, Fizz1, and Alox-12e 
mRNA in lung macrophages from WT and Ja18–/– mice at PI Day 49. For (b,d,e), (*) 
indicates a significant increase from PI Day 0 or SeV-UV control. 
Supplementary Figure 8 
Supplementary Figure 8. Increased IL-13-producing macrophages in humans 
with asthma. (a) Representative photomicrographs of cytospin samples from 
BAL fluid of severe asthma patients and normal control subjects that were 
immunostained for IL-13 and CD68. Arrows indicate a representative IL-
13+CD68+ macrophage. Bar = 20 µm. (b) Quantitative analysis of IL-13 and 
CD68 immunostaining from (a) in asthma patients (n = 3) and non-asthma control 




Mice generation and treatment. All mice were maintained under pathogen-free conditions for study at 6-
8 wk of age as described previously 1-4. Sentinel mice and experimental control mice were handled 
identically to inoculated mice and exhibited no serologic or histologic evidence of exposure to 11 rodent 
pathogens (including SeV). For IL-4 blockade, anti-IL-4 mAb (clone 11B.11) was administered at 200 
µg/kg by intraperitoneal injection at 3-day intervals from Day 12 to 49 after viral inoculation as described 
previously 5. For CD4 and CD8 blockade, anti-CD4 mAb (clone YTS 191.1) and anti-CD8 mAb (clone 
2.43) were administered on the same schedule as anti-IL-4 mAb and were delivered at levels that inhibit 
the airway response to allergen 6-8.  
Analysis of mRNA and SeV-specific RNA. For analysis of lung mRNA levels, sequences of the forward 
and reverse primers and probes were: 5’-GGAGCTGAGCAACATCACACA-3’, 5’-
CACACTCCATACCATGCTGCC-3’, and 5’-CCAGACTCCCCTGTGCA-3' for Il-13; 5’-
TACCACTCCCTGCTTCTGCAGCGTGTCA-3’, 5’ATAGTAACAGTGGCCATCAAGGTCTGTCT3’, 
and 5’-TATACCCCTTGGGATCCATCATCTACA-3’ for Muc5ac; and 5’-CATGGAGCTGCAGAGA-
CTCTTTCGGGCT-3’, 5’-AAGTCTTTCAGTGATGTGGACTTGGAC-3’ and 5’-ATGCCTGGATTC-
ATCGATAAGCTGCACCAT-3’ for Il-4; 5’-CTTGTCACAGGTCTGGCAATTC-3’, 5’-GTAGCACA-
TCAGCTGGTAGGAAGA-3’, and 5’-TCTGAACGTACAGCTGGG-3’ for Chi3l3/4; and 5’-
ATGAACAGATGGGCCTCCTG-3’, 5’-AGCCACAAGCACACCCAGTAG-3’, and 5’-
CCTGCTGGGA-TGACT-3’ for Fizz1. All probes were designed to span an intron and did not react with 
genomic DNA. Levels of Ifn-β, Ifn-γ, Il-13ra1, Mmp12, Arg1, Alox-12e, Ccl2, Ccl3, Ccl4, Ccl5, and 
Gapdh mRNA were determined using Taqman gene expression assays (Applied Biosystems). Viral titer 
was monitored by quantitative real-time PCR for SeV-specific RNA using 5’-
CCACCCTGAGGAGCAGGTT (viral nt 68-85) as forward primer, 5’-CCCGGCCATCGTGAACT (nt 
112-129) as reverse primer, and 5’-CAAAGCAAAGGGTCTG (nt 87-110) as MGB probe. Part of the 
SeV genome (nt 5-620) that includes leader sequence and part of the nucleocapsid protein (NP) gene was 
cloned into pGEM-3Zf(-) plasmid, and transcript in genomic orientation was used as RNA standard. All 
mRNA and SeV-specific RNA levels were normalized to levels of Gapdh mRNA using the TaqMan 
Rodent GAPDH Control Kit. 
For oligonucleotide microarray analysis, whole lung RNA from PI Days 21 and 49 was used to generate 
labeled cRNA that was hybridized in triplicate to oligonucleotide microarrays (Affymetrix Mouse 
Expression Set 430 for PI Day 21, Affymetrix Mouse Genome Array 430 2.0 for PI Day 49) and scanned 
as described previously 9. Microarray normalization and statistical analysis was performed using packages 
from the Bioconductor project 10 executed in the R programming environment. We normalized data using 
the empirical Bayes version of the GCRMA algorithm as implemented in the GCRMA package 11. We 
assessed differential expression (SeV versus SeV-UV) using linear models and empirical Bayes 
moderated F statistics as implemented in the LIMMA package 12. We considered differences in gene 
expression significant if P values were <0.05 after adjustment for multiple testing as described previously 
13, so that false discovery rate was <5%. We performed visualization and plotting using Spotfire 
DecisionSite for Functional Genomics (Spotfire).  
Cell isolation and culture. Lung cell suspensions were generated using a protocol modified from one 
described previously 14. For the present experiments, PBS was used to flush out the pulmonary and 
systemic circulations, and BAL was performed to remove any cells in the bronchiolar or alveolar space. 
Next, 1 ml of digest media was injected intratracheally. Digest medium consisted of DME supplemented 
with 5% fetal calf serum, 10 mM HEPES, penicillin/streptokinase, 250 U/ml collagenase type I 
(Worthington Biochemical), 50 U/ml DNase I (Worthington Biochemical), and 0.01% hyaluronidase 
(Sigma-Aldrich). The lungs were carefully dissected from the trachea, main-stem bronchi, draining lymph 
nodes, and surrounding tissue, and then were minced and incubated in digest media for 1 h at 37 °C. 
During the final 15 min of incubation time, EDTA was added to a final concentration of 2 mM. After 
digestion, the cell mixture was passed through a 40-µm cell strainer to generate single-cell suspensions, 
and erythrocytes were removed by hypotonic lysis.  
For analysis by flow cytometry, samples were blocked with 1 µg anti-mouse CD16/CD32 (BD 
Pharmingen) per 1 x 106 cells for 15 min, and then stained with mAb (Pharmingen or eBioscience) 
conjugated to appropriate flurophores for 30 min at 4 °C. Labeled rat anti-mouse c-kit, FceRI, GR-1, 
CD11c, CD19, B220, DX5, NK1.1, CD4, CD8, Mac1, Mac3, FcεRIα, and MHC Class II as well as 
hamster anti-mouse CD3e and isotype control IgGs (rat and Armenian hamster) were from eBioscience or 
BD Pharmingen. For intracellular staining for CD68, cells were fixed with 2% paraformaldehyde for 15 
min at 4 °C and permeabilized with Perm/Wash buffer (BD Biosciences) for 30 min for intracellular 
staining with rat anti-mouse CD68 mAb (Serotec). Cells were sorted by FACS using a MoFlo high-speed 
flow cytometer (Dako Cytomation). Cells were collected in either RLT lysis buffer (Qiagen) for RNA 
isolation or HBSS for further experimentation with viable cells. 
Cells were sorted as follows: anti-c-kit positive for mast cells, anti-FcεRIα positive for basophils, anti-
GR-1 positive for neutrophils, and anti-CD11c positive for DCs. The B, T, NK, NKT cells, and 
macrophages were gated for FSCmediumSSClow “lymphocytes”. Within this gate, we sorted anti-B220 
positive or CD19 positive for B cells (both gave identical results), both anti-CD8 and anti-CD3e positive 
for CD8+ T cells, anti-CD4 and anti-CD3e positive as CD4+ T cells, anti-DX5 positive and anti-CD3e 
negative for NK cells, anti-NK1.1 positive and anti-CD3e positive or α-GalCer analogue (PBS57)-loaded 
CD1d tetramer positive and anti-CD3e positive for NKT cells; anti-Mac-1 positive and intracellular anti-
CD68 positive or anti-Mac-1 positive and negative for a pool of FITC-label anti-c-kit, FcεRI, GR-1, 
CD11c, NK1.1, CD3e, and B220 mAbs for macrophages. The latter sort scheme (Mac1-positive, multiple 
FITC marker-negative macrophages) were >95% positive for intracellular CD68 on subsequent analysis 
and allowed us to perform further experiments with non-permeabilized live cells. Macrophages were also 
gated for FSCmedSSClow “macrophages-granulocytes”, but little Il-13 mRNA was detected in cells in this 
gate (<4% of total Il-13 mRNA at PI Day 49). Thus, all data for Il-13 mRNA is derived from cells found 
in the FSCmediumSSClow gate. Levels of IL-13 and chemokine (KC, CCL2, CCL3, CCL4, and CCL5) 
proteins were determined by Quantikine, ELISA (R&D Systems) or Bio-Plex bead-based cytokine assay 
(Bio-Rad), respectively.  
Immunohistochemistry. For immunostaining with brightfield microscopy, mouse lungs were fixed, 
embedded in paraffin, cut into sections, dewaxed, rehydrated, and incubated with mouse anti-MUC5AC 
mAb (clone 45M1; Neomarkers) or control Ab as described previously 1-3. Tissue sections were 
counterstained with hematoxylin, dehydrated in graded ethanol, and mounted for viewing in a 
photomicrography system. For immunofluorescence, paraffinized sections were hydrated and incubated in 
Antigen Unmasking Solution (Vector Labs) at 90 °C for 10 min for antigen retrieval. Sections were 
blocked for 1 h at 25 °C in 2% vol/vol teleostean gelatin (Sigma) and 5% goat serum and then overnight at 
4 °C with biotinylated goat anti-mouse IL-13 Ab (R&D Systems, 3.6 µg/ml). Staining was visualized with 
tyramide signal amplification Alexa Fluor 555 (Invitrogen). Peroxidase activity was quenched with 3% 
H2O2 for 5 min at 25 °C. Biotin, biotin receptors, and avidin binding sites were blocked with the 
Avidin/Biotin Blocking kit (Vector Labs). Sections were also stained with biotinylated rat anti-mouse 
CD68 mAb (Serotec, 10 µg/ml) followed by avidin HRP (Vector Elite ABC System) and Alexa Fluor 488 
(Invitrogen) and with goat anti-mouse IL-13Rα1 IgG (Santa Cruz Biotechnology, 2 µg/ml) followed by 
biotinylated donkey anti-goat IgG mAb (Jackson Immunoresearch, 13 µg/ml) and Alexa Fluor 647 
(Invitrogen). Sections were treated wit 3% H2O2 for 5 min at 25 °C and the Avidin/Biotin Blocking kit. 
All antibodies were incubated in PBS with 2% vol/vol teleostean gelatin. Sections were counterstained 
with 4’6-diamidino-2-phenylindole (DAPI). In some experiments, tissue sections were blocked with 2% 
teleostean gelatin, incubated with biotinylated anti-MUC5AC mAb and Alexa 555-conjugated streptavidin 
or anti-CD68 mAb and Alexa 633-conjugated goat anti-rabbit secondary Ab (Molecular Probes), 
counterstained with Sytox Green (Molecular Probes), and then imaged by confocal microscopy using a 
Zeiss laser scanning system with LSM-510 software. For immunostaiining of Chi3l3/4 (Ym1), rabbit anti-
mouse Chi3l3/4 Ab was provided by Shioko Kimura (NCI, Bethesda, MD) and used as described 
previously 15.  
Airway reactivity measurements. In screening experiments, airway reactivity to nebulized methacholine 
was determined in unrestrained mice using a whole-body plethysmograph and BioSystem XA Version 
2.7.9 software (Buxco Electronic) to derive values for enhanced pause (Penh) as described previously 2,16. 
Mice were placed in the plethysmograph for a 5-min acclimatization interval, followed by 3-min 
acquisition intervals before (baseline Penh) and after a 48-sec exposure to nebulized vehicle (PBS) or 
doubling concentrations of methacholine (5-80 mg/ml) delivered from a Collison 6 jet nebulizer (BGI). In 
validation experiments, airway reactivity was also determined by measurements of total lung resistance 
(RL) and dynamic compliance (Cdyn) as described previously 16. In this case, mice were anesthetized with 
pentobarbital (100 mg/kg ip), ventilated through a tracheostomy with a Harvard Apparatus Model 687 at 
6-10 ml/kg and positive end-expiratory pressure of 2-4 cm H20, and monitored for intrapleural pressure 
using an oroesophageal tube. Methacholine was delivered at 3-min intervals using an in-line nebulizer 
(Aerogen Laboratory; 2.4-4 µm particle size). Between deliveries, respiratory flow signal was obtained 
with a pneumotach (SenSym SCXL004; Buxco Electronics) and was integrated to calculate lung volume. 
Intraesophageal and airway pressure were measured via pressure transducers (Validyne DP45; Buxco 
Electronics) directly connected to the respective catheters.  
Human subject samples. Patients with severe asthma as well as healthy control subjects were recruited, 
characterized, and subjected to bronchoalveolar lavage (BAL) as described previously 1,3,17,18. Severe 
asthma patients met the American Thoracic Society workshop criteria for refractory severe asthma if they 
had one or both of two major criteria and two of the minor criteria 19. The major criteria include: treatment 
with continuous or near continuous oral glucocorticoids or treatment with high-dose inhaled 
glucocorticoids. The minor criteria include: daily treatment with a long-term controller medication in 
addition to inhaled glucocorticoids, asthma symptoms requiring short-acting β-agonist use on a daily or 
near-daily basis, persistent airflow obstruction, one or more urgent care visits for asthma per year, three or 
more oral glucocorticoid bursts per year, prompt deterioration with <25% decrease in oral or inhaled 
glucocorticoid dose, or near fatal asthma event in the past. For the group of severe asthma patients, forced 
expiratory volume in 1 sec (FEV1) was 63 ± 14% predicted, and for normal controls, FEV1 was 86 ± 4% 
predicted. For asthma and control subjects, there was no history of endotracheal intubation within the past 
5 yr, respiratory tract infection within the past 3 months, or significant cardiac or neurologic disease. 
Cytospin samples from BAL fluid were immunostained with mouse anti-human CD68 mAb (2 µg/ml) for 
18 h that was visualized with anti-mouse HRP mAb (Invitrogen, 1 µg/ml) followed by tyramide signal 
amplification with Alexa Fluor 488 (Invitrogen), quenched with HCl, and then stained with biotinylated 
mouse anti-human IL-13 mAb (4 µg/ml) for 18 h that was visualized with avidin HRP (Vector Elite ABC 
System) and Alexa Fluor 594 (Invitrogen).  
For COPD patients, real-time PCR was performed in the same manner as described above for mouse lung. 
Sequences of forward and reverse primers and probes were: AGGCCAGCTACCGGGCCG-
GCCAGACCAT, 5’-GTCCCCGTACACGGCGCAGGTGGCCAGGCA, and 5’-TGCAACACCTGC-
ACCTGTGACAGCAGGAT for MUC5AC, 5’- GAAGACCCAGAGGATGCTGAGCGGATTCT, 5’-
ACCTCGATTTTGGTGTCTCGGACA, and 5’-AAGGTCTCAGCTGGGCAGTTTTCCAGCTTG for IL-
13, 5’-5’CAGCCGAGCCACATCCCTCAGACACCAT, 5’-CTTTACCAGAGTTAAAAGCAGCCC-
TGGTGACCA, and 5’-AGGTCGGAGTCAACCGATTTGGTCGTATTG for GAPDH. All target mRNA 
levels were normalized to GAPDH mRNA levels. 
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